Health Disparity Clusters of Off Label Prescriptions for Glucagon-like Peptide 1 Receptor Agonists

American Journal of Medicine Open, Journal Year: 2025, Volume and Issue: unknown, P. 100100 - 100100

Published: April 1, 2025

Language: Английский

Utilizing AI and Social Media Analytics to Discover Adverse Side Effects of GLP-1 Receptor Agonists

SSRN Electronic Journal, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Adverse side effects (ASEs) of drugs, revealed after FDA approval, pose a threat to patient safety. To promptly detect overlooked ASEs, we developed digital health methodology capable analyzing massive public data from social media, published clinical research, manufacturers' reports, and ChatGPT. We uncovered ASEs associated with the glucagon-like peptide 1 receptor agonists (GLP-1 RA), market expected grow exponentially $133.5 billion by 2030. Using Named Entity Recognition (NER) model, our method successfully detected 21 potential upon including irritability numbness. Our data-analytic approach revolutionizes detection unreported newly deployed leveraging cutting-edge AI-driven media analytics. It can increase safety new drugs in marketplace unlocking power support regulators manufacturers rapid discovery hidden ASE risks.

Language: Английский

Cost-Related Prescription Drug Rationing by Adults With Obesity

JAMA Network Open, Journal Year: 2024, Volume and Issue: 7(11), P. e2433000 - e2433000

Published: Nov. 5, 2024

This cross-sectional study analyzes data from the National Health Interview Survey to examine prevalence of cost-related prescription drug rationing by adults with obesity.

Language: Английский